Register for E-mail alerts. Comment on articles. Sign up today, it's easy.
Close
The Washington Times Online Edition

Silver Spring firm moves to testing of its cancer drug

United Therapeutics Corp. yesterday said it moved one step closer to federal government approval for its ovarian cancer drug, OvaRex.

The Silver Spring biotechnology company, which has reported solid sales growth for its only marketed drug, Remodulin, said it reached its goal of enrolling 177 patients for one of two patient studies for OvaRex.

“This doesn’t mean the drug works any better or worse, but it is a nice milestone,” said company spokesman Andrew Fisher.

United Therapeutics has no timetable for when the studies will be completed or when it will receive a final decision from the Food and Drug Administration, Mr. Fisher said.

The announcement comes a month after the company’s shares on the Nasdaq Stock Market reached a record high of $77.82, three days after United Therapeutics released its latest earnings report. Company shares fell 55 cents yesterday to close at $70.34.

Net income for the company’s third quarter, ended Sept. 30, more than doubled to $15.76 million (61 cents per diluted share) from $6.26 million (27 cents) a year earlier. Fully diluted earnings include the value of convertible warrants and stock options.

Revenue jumped 65 percent to $33 million from $19.9 million in the 2004 quarter.

United Therapeutics has an undisclosed number of drugs in development, but OvaRex is the closest to getting FDA approval, Mr. Fisher said.

But analysts yesterday were more interested in developments for Remodulin, which treats rare lung disorder pulmonary arterial hypertension.

OvaRex “is a wait-and-see product,” said analyst Gil Aharon, estimating that the drug’s tests would take another two years to produce results.

Mr. Aharon, with Toronto investment firm Infinium Capital Corp., said he rated United Therapeutics shares “outperform,” based on the sales strength of Remodulin.

Mr. Aharon does not own any company stock, but Infinium is seeking business with United Therapeutics.

Remodulin is sold through an injection administered just under a patient’s skin or via a newer intravenous (IV) version, which is injected directly into a patient’s vein. United Therapeutics also is developing an oral and inhaled version of the drug.

The IV treatment has drawn some patients away from Flolan, an intravenous treatment for the same disorder by GlaxoSmithKline.

Joseph Schwartz, an analyst with Boston investment bank Leerink Swann & Co., said doctors might need more clinical data before switching patients to Remodulin.

Story Continues →

View Entire Story
Comments
blog comments powered by Disqus
You Might Also Like
  • (Associated Press photographs)

    Worried conservatives descend on Washington’s CPAC

    By Ralph Z. Hallow - The Washington Times

  • Retired Army Gen. Jack Keane

    General: ‘Use drones to kill’ the Taliban in Pakistan

    By Rowan Scarborough - The Washington Times

  • **FILE** An auction sign is shown outside the Fremont, Calif., headquarters for bankrupt solar company Solyndra headquarters on Oct. 31, 2011, before the auction on the following day. Solyndra received a $500 million loan guarantee from the government before filing for bankruptcy in September. (Associated Press)

    Solyndra sold assets cheap for fast cash

    By Jim McElhatton - The Washington Times

  • In Case You Missed It
    Talk of the Web
    Happening Now

          Independent voices from the TWT Communities

          Middle Class Guy

          What does the middle-class conservative think about everything? Find out here.

          Culinary Quest

          Great discoveries in the world of restaurants and chefs fulfill the quest for delicious food and cooking.

          Legally Speaking

          Despite cynicism about the law, it can provide you justice, protection, and ensure your rights. It can be exasperating, and at times, wildly entertaining.